GLP3-R
15mg
⚠️ Not for human consumption. Research purposes only.
Description
GLP3-R is a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, investigated in preclinical metabolic research for its multi-receptor binding pharmacology. Published data characterize its affinity profiles across all three incretin/glucagon receptor subtypes, with downstream effects on cAMP signaling, hepatic lipid oxidation, and energy-expenditure pathways in rodent models. Supplied as a 15mg lyophilized vial for in vitro and in vivo laboratory use only.
Key Areas of Study
- Triple incretin/glucagon receptor binding analysis
- hepatic lipid oxidation pathway studies
- energy-expenditure modeling
- multi-receptor signaling crosstalk research
Mechanisms Being Evaluated
Simultaneously engages GLP-1, GIP, and glucagon receptor subtypes, activating parallel adenylyl cyclase–cAMP cascades. Preclinical models demonstrate modulation of hepatic fatty-acid oxidation via glucagon-receptor signaling, alongside incretin-mediated insulin secretion kinetics and hypothalamic satiety-circuit activation.
Commonly Researched Uses
Multi-receptor agonist pharmacology research, hepatic lipid metabolism studies, incretin signaling pathway analysis, energy-expenditure modeling in preclinical settings